A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
require that the label of drugs with an increased risk 
of suicide or depression present such increased risk 
prominently, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Depression Side Effect 
4
Labeling Awareness Act of 2019’’. 
5
23:36 Sep 20, 2019
H4404
2 
•HR 4404 IH
SEC. 2. PROMINENT DRUG LABELING FOR INCREASED RISK 
1
OF SUICIDE OR DEPRESSION. 
2
(a) IN GENERAL.—Section 502 of the Federal Food, 
3
Drug, and Cosmetic Act (21 U.S.C. 352) is amended by 
4
adding at the end the following: 
5
‘‘(ee) If the warnings and precautions in the drug’s 
6
label include an increased risk of suicide or depression, 
7
unless such increased risk is presented prominently.’’. 
8
(b) REGULATIONS.—Not later than 1 year after the 
9
date of enactment of this Act, the Secretary of Health and 
10
Human Services, acting through the Commissioner of 
11
Food and Drugs, shall promulgate final regulations to 
12
carry out section 502(ee) of the Federal Food, Drug, and 
13
Cosmetic Act, as added by subsection (a). Before promul-
14
gating such regulations, the Secretary shall consult with 
15
stakeholders, including manufacturers of drugs. 
16
(c) DELAYED APPLICABILITY.—Such section 502(ee) 
17
shall not apply until the Secretary of Health and Human 
18
Services has issued a final regulation under subsection (b). 
19
Æ 
23:36 Sep 20, 2019
H4404
